Jobs / United States / Astrazeneca Pharmaceuticals Lp
Director, Portfolio, Resourcing and Transformation
Astrazeneca Pharmaceuticals Lp · 🇺🇸 US - Cambridge Kendall SQ - MA
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles1 certified filing for “Associate Director, Oncology Portfolio Analytics” (Management Analysts) in MD: $157k–$157k, median $157k. Most were filed at wage level II (100%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
About the role At AstraZeneca, we’re not afraid to do things differently. We’re building a new kind of organization to reset expectations of what a bio-pharmaceutical company can be. This means we’re opening up new ways to work, pioneering ground-breaking methods and bringing cross-functional teams together. Biologics Engineering (BE) and Oncology Targeted Discovery (OTD) are pivotal organizations of over 1,000 people building the AstraZeneca portfolio across Biopharmaceuticals, Oncology and Infectious Diseases. With our ambition of delivering 20 new medicines by 2030, we must decide clearly where to invest our scientific capacity, bring AI into how we discover and develop medicines, and build next-generation talent. This role sits where science, portfolio and transformation meet. You will shape how our scientific capacity is allocated across therapy areas, and how we decide what to start, continue, slow or stop. And you will lead strategic and transformation projects, including bringing AI into how we work, with direct exposure to senior scientific and functional leadership. The ideal candidate combines analytical difficulty with the standing to align senior leaders who do not report to them. They are as comfortable facilitating a decision between Vice Presidents as they are building the numbers that make that decision possible, and they hold both to the same standard. You will be responsible for • Portfolio resource allocation and decision-making • Run the resource allocation process with leadership teams and therapy area representatives, starting in BE, with scope to extend across the wider organization over time. • Partner with the teams that produce resourcing actuals to improve existing reports, put the numbers in context, and turn them into inputs for decisions, so that allocation is decided rather than left to drift. • Ensure new work starts only where capacity exists or a named release is agreed, and that work is slowed or stopped through scheduled reviews and clear triggers, in partnership with the leaders who own those decisions. • Keep a clear record of allocation decisions and their expected effect on capacity and check the delivered effect against actuals. • Evolve the methodology, rules and forums as needs change and adapt them as new parts of the organization come into scope. 2. Strategic projects and transformation • Lead high-impact strategic projects for the leadership teams of BE and OTD, from framing the question through to recommendation and implementation. • Drive delivery of AI transformation programs: turn ambition into a clear roadmap, and set up the governance, cadence and reporting that keep it on track. • Bring senior leaders across departments behind shared priorities, and resolve interdependencies, resourcing questions and decisions as they arise. • Projects may also include operating model and organizational design choices, evaluating new capabilities and technology platforms, building investment cases, and portfolio and competitive analyses that inform where to focus. • Track delivery and value against agreed objectives, connect initiatives to portfolio and resourcing plans, and bring risks and decisions to sponsors early. • Assemble and lead cross-functional project teams and develop the people in them. • Build outcomes into ongoing ways of working and help what works spread across the wider organization. 3. Leadership and organizational effectiveness • Shape the governance cadence of the leadership teams you support agendas, pre-reads, and decisions and actions followed through to completion. • Track and report progress against goals and scorecard critical metrics, and flag risks to delivery early. • Own recurring operating processes end to end, so they run reliably without